Research · Sep 3, 2026
[NDSN] Nordson Thesis 2026: 62-Year Dividend Aristocrat Tests Industrial Cycle Recovery
Nordson Corporation (NASDAQ: NDSN) FY2025 (fiscal year ending October 2026) revenue ~$2.6-2.8B (+0-5%) with adj. EPS ~$8.50-10.00 reflecting continued post-2024 industrial cycle weakness affecting selected packaging + selected industrial customers + selected April 2024 ARAG Group $960M precision agriculture acquisition partial-year contribution + selected ~62-year continuous dividend track (longest NASDAQ dividend record) + selected Medical & Fluid + Advanced Technology segment diversification under continued CEO Sundaram Nagarajan (~6-year tenure since August 2019). Leading global precision dispensing + adhesive systems firm focused on industrial precision dispensing technology + medical fluid components + advanced technology systems. Founded 1954 by Eric Nord as Nordson Corp in Amherst Ohio (~71-year heritage; selected initial focus on industrial adhesive dispensing); IPO 1971 NASDAQ; selected various transformative acquisitions through history including selected 2010 EDI $200M + selected 2017 Vention Medical $705M + selected 2022 CyberOptics $380M + selected April 2024 ARAG Group $960M. Headquartered in Westlake Ohio; ~7,800+ employees globally with ~$2.6-2.8B revenue. Three reporting segments: Industrial Precision Solutions ~50% revenue ($1.4B — selected adhesive dispensing + polymer processing + non-woven systems + post-2024 ARAG Group precision agriculture), Medical & Fluid Solutions ~25% ($700M — selected medical device fluid components + interventional + post-2017 Vention Medical integration), and Advanced Technology Solutions ~25% ($700M — selected electronics dispensing + test/inspection + post-2022 CyberOptics integration). 62-year dividend aristocrat: ~62 consecutive year continuous dividend increases (since 1956) representing selected longest dividend track record on NASDAQ exchange + one of longest in S&P 500; ~$2.72-2.85/share annual FY2025 (~$0.68-0.71/quarter; ~5-10% annual increases; dividend yield ~1.0-1.5%); FY2026 expected dividend toward $2.90-3.10 (+5-10%) maintaining ~63-year dividend continuity. Industrial Precision Solutions cycle: $1.4B FY2025 (~50% of total; +0-5% YoY); selected adhesive dispensing (packaging + non-woven hygiene + consumer non-durables) + polymer processing (plastics extrusion); selected post-2024 industrial cycle weakness; April 2024 ARAG Group $960M acquisition (~$200M+ FY2025 revenue contribution; $50-75M expected cost synergies + revenue cross-sell); FY2026 expected IPS toward $1.45-1.55B (+3-7%) on industrial cycle recovery + ARAG full-year + precision agriculture market expansion. CEO Sundaram Nagarajan since August 2019 (succeeded Michael Hilton CEO 2010-August 2019 retired who led 2010-2019 strategic transformation including 2017 Vention Medical $705M; Nagarajan ex-Illinois Tool Works VP/General Manager + ~25-year industrial career; Indian-American). Capital return: ~$2.72-2.85 annual dividend FY2025 (~62-year continuous increases); modest buybacks $50-200M FY2025 (post-ARAG deleveraging); investment-grade A2/A credit ratings reflect disciplined capital allocation + stable cash flow generation through industrial cycles. FY2026 thesis: industrial cycle recovery + ARAG integration + ~63-year dividend track + buyback resumption. Risks: major industrial cycle reversal, ARAG integration impairment, Graco competitive intensity, currency translation severe.